Production (Stage)
Atea Pharmaceuticals, Inc.
AVIR
$2.90
$0.051.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -34.27M | -33.54M | -31.15M | -40.52M | -63.17M |
| Total Depreciation and Amortization | 104.00K | 104.00K | 104.00K | 104.00K | 104.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.21M | 11.58M | 9.57M | 9.70M | 9.10M |
| Change in Net Operating Assets | -1.61M | -8.54M | -1.56M | -11.48M | 14.10M |
| Cash from Operations | -30.56M | -30.40M | -23.04M | -42.20M | -39.87M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 85.61M | -3.37M | -122.01M | 124.69M | 56.80M |
| Cash from Investing | 85.61M | -3.37M | -122.01M | 124.69M | 56.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 138.00K | 0.00 | 117.00K | 0.00 | 150.00K |
| Repurchase of Common Stock | -485.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -347.00K | 0.00 | 117.00K | 0.00 | 150.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 54.70M | -33.77M | -144.93M | 82.48M | 17.09M |